For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

High Rates of Durable Responses2,5

  • Up to 69% of patients responded to therapy5
  • Median duration of response (DOR) up to 13.8 months, with complete responders demonstrating a median DOR of up to 39.6 months2

Find out more

Well-Characterized and Consistent Safety Profile2,5,6

Across 2 phase 3 studies, Tafinlar + Mekinist demonstrated similar incidences of AEs and discontinuation rates compared with BRAF inhibitor monotherapy2,5

Find out more

Initiate First-Line Treatment With Tafinlar® + Mekinist®

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma6

Find out more

References: 1. Flaherty KT, Davies MA, Grob J, et al. Genomic analysis and 3-year efficacy and safety update of COMBI-d. J Clin Oncol. 2016;34(suppl) [abstract 9502]. 2. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Presented at: European Society for Medical Oncology Annual Meeting; October 7-11, 2016; Copenhagen, Denmark. 3. Schadendorf D, Amonkar MM, Stroyakovskiy D, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51(7):833-840. 4. Grob J-J, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389-1398. 5. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451. 6. Tafinlar (dabrafenib) [summary of product characteristics]. West Sussex, UK: Novartis Europharm Limited; 2016.